Peptide Microarray for SARS-CoV-2 Antibody Detection and Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and vaccine development for SARS-CoV-2 is limited by a lack of understanding of the humoral response, particularly regarding antibodies to structural and non-structural proteins, and the ability to distinguish between past infection and vaccination status.
Innovation Solution
The use of an ultra-dense peptide microarray to profile antibody binding across the SARS-CoV-2 proteome, enabling the detection of antibodies through specific peptides and differentiation between infected, vaccinated, and naive individuals, as well as the development of a vaccine composition incorporating these peptides to elicit an immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If serology-based testing platforms use spike or nucleocapsid proteins as antigens, then detection sensitivity is achieved (79.6%-91.7%), but the ability to distinguish between past infection and vaccination status is limited
Solution Approach 1:
The patent segments the SARS-CoV-2 proteome into multiple distinct peptide regions including spike protein, nucleocapsid protein, membrane protein, and non-structural proteins. By testing antibodies against multiple segmented targets rather than single proteins, the assay can distinguish infection patterns - vaccinated individuals typically show only spike antibodies while naturally infected individuals show antibodies against multiple protein segments
Solution Approach 2:
The patent creates a multi-functional diagnostic platform that simultaneously performs sensitivity detection and infection status differentiation. The same microarray platform detects both the presence of antibodies (sensitivity) and the pattern of antibody responses across multiple targets (specificity for infection vs vaccination), making the system universally applicable for both purposes
2Ease of manufacture
If antibody responses are profiled only against spike and nucleocapsid proteins, then current diagnostic capabilities are maintained, but understanding of the full humoral response to SARS-CoV-2 remains limited
Solution Approach 1:
The patent adds another dimension to antibody profiling by expanding from two protein targets (spike and nucleocapsid) to comprehensive coverage of the entire SARS-CoV-2 proteome including membrane protein, non-structural proteins, and accessory proteins. This dimensional expansion provides a much broader view of the humoral response while maintaining platform feasibility through peptide microarray technology
3Loss of time
If the focus remains on nucleocapsid antibodies for detection, then current diagnostic methods are sufficient, but the duration of detectable antibodies is limited compared to membrane protein antibodies
Solution Approach 1:
The patent performs preliminary identification of membrane protein epitopes and other long-lasting antibody targets before deploying the diagnostic assay. By pre-characterizing which protein regions produce the most durable antibody responses, the platform is optimized to detect antibodies over extended periods, allowing clinicians to use the test much later in the infection course and still obtain positive results
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides sensitive and specific detection of SARS-CoV-2 antibodies and differentiation between infection and vaccination, enhancing diagnostic accuracy and vaccine efficacy by targeting multiple protein epitopes, including the membrane protein, which remains detectable for longer periods than nucleocapsid antibodies.
Implementation Method 1
detecting the binding of one or more antibodies from the sample to the one or more peptide
Data Source
AI summary
The present invention is directed to peptides for use in the detection of antibodies against SARS-CoV-2, which are indicative of past SARS-CoV-2 infections. Additionally, assays and methods of distinguishing patients having had a prior infection from those vaccinated patients are also provided. Additionally, vaccine compositions for use in eliciting anti-SARS-CoV-2 immune response are provided along with methods of producing antibodies and methods of eliciting an immune response.